Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00180492 · ClinicalTrials.gov registry record · NA

Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems: CAPTURE

A NA study of Atherosclerotic Disease, Carotid, sponsored by Abbott Medical Devices.

Completed
Registry status
NA
Development phase
1,500
Enrollment target
1
Study location

NCT00180492: Completed NA study of Atherosclerotic Disease, Carotid, sponsored by Abbott Medical Devices.

NCT00180492 is a NA study of Atherosclerotic Disease, Carotid that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,500 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00180492, a NA study of Atherosclerotic Disease, Carotid, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
NA
Development phase
1,500 participants
Enrollment target
1
Study location

Study Summary

This purpose of this study is to collect data on the FDA-approved ACCULINK(TM) Carotid Stent System and FDA 510(k)-cleared ACCUNET(TM) Embolic Protection System for the treatment of patients with atherosclerotic disease, when used by physicians under commercial use conditions.

Interventions

  • DEVICE RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System

Study Locations (1)

California

  • Guidant Corporation - Santa Clara

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2004-10
Est. Completion 2007-08
Phase NA
Abbott Medical Devices

261 total trials

What the finished NCT00180492 record still lists

NCT00180492 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.

The record links to 1 condition, with Atherosclerotic Disease, Carotid appearing as the primary indexed condition, and to 1 intervention - of which RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System is the first listed.

NCT00180492 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00180492 about?

NCT00180492 is a clinical study titled "Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems: CAPTURE". This purpose of this study is to collect data on the FDA-approved ACCULINK(TM) Carotid Stent System and FDA 510(k)-cleared ACCUNET(TM) Embolic Protection System for the treatment of patients with atherosclerotic disease, when used by physicians under commercial use conditions.

What is the current status of trial NCT00180492?

This trial is currently completed. It is a NA study. The enrollment target is 1,500 participants. The study started on 2004-10. Estimated completion is 2007-08.

What conditions does trial NCT00180492 study?

This clinical trial studies the following conditions: Atherosclerotic Disease, Carotid.

What interventions are being tested in trial NCT00180492?

The interventions under investigation include: RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System (DEVICE).

Who is sponsoring clinical trial NCT00180492?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00180492 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT00180492's enrollment target sits among peer trials

1,500 65th of 2000 higher than 1,933 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00178724 · 1,500 participants

    Spinal Cord Injury Registry - North American Clinical Trials Network

  • NCT00951366 · 1,500 participants

    Preterm Lung Patient Registry

  • NCT01050504 · 1,500 participants

    Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

  • NCT02071134 · 1,500 participants

    Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00180492, the US trial registry maintained by the National Library of Medicine. NCT00180492 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.